HPR.F - Horizon Pharma Public Limited Company

Frankfurt - Frankfurt Delayed price. Currency in EUR
26.18
-0.42 (-1.58%)
As of 9:04AM CEST. Market open.
Stock chart is not supported by your current browser
Previous close26.60
Open26.18
Bid25.52 x 14500
Ask26.80 x 13900
Day's range26.18 - 26.18
52-week range20.00 - 34.60
Volume100
Avg. volume11
Market cap5.165B
Beta (5Y monthly)0.94
PE ratio (TTM)9.02
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Horizon Pharma PLC (HZNP) Q2 2019 Earnings Call Transcript
    Motley Fool

    Horizon Pharma PLC (HZNP) Q2 2019 Earnings Call Transcript

    HZNP earnings call for the period ending June 30, 2019.

  • Here's How Horizon Therapeutics Blew Past Wall Street Estimates in Q1
    Motley Fool

    Here's How Horizon Therapeutics Blew Past Wall Street Estimates in Q1

    Strong growth for its orphan, rheumatology, and primary care drugs translated to a great first quarter for Horizon.

  • Horizon Pharma PLC (HZNP) Q1 2019 Earnings Call Transcript
    Motley Fool

    Horizon Pharma PLC (HZNP) Q1 2019 Earnings Call Transcript

    HZNP earnings call for the period ending March 31, 2019.

  • Associated Press

    Horizon Pharma: 1Q Earnings Snapshot

    On a per-share basis, the Dublin-based company said it had a loss of 19 cents. Earnings, adjusted for non-recurring costs, came to 30 cents per share. The results surpassed Wall Street expectations. The ...

  • In Canada, a little-known drug regulator shows its teeth
    Reuters

    In Canada, a little-known drug regulator shows its teeth

    A tiny, little-known government agency is ramping up regulation of Canada's pharmaceutical industry, seeking to rein in prices for patented drugs that are among the highest in the world, according to industry sources and a Reuters analysis of government data. The federal Patented Medicine Prices Review Board (PMPRB) is targeting an increasing number of expensive drugs, including a rare-disease medication made by Horizon Pharma that can cost C$325,000 ($253,409) a year, documents reviewed by Reuters shows. The agency can challenge the list price of any patented drug in Canada and order companies to repay some revenue.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more